18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3332-3340

  McKinley, Eliot T ^a,b   Bugaj, Joseph E ^e   Zhao, Ping ^a   Guleryuz, Saffet ^a   Mantis, Christine ^e   Gokhale, Prafulla C ^e   Wild, Robert ^e   Manning, H Charles ^a,b,c,d  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OSI PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN RECEPTOR; LINSITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C RECEPTOR; 3 (8 AMINO 1 (2 PHENYLQUINOLIN 7 YL)IMIDAZO(1,5 A)PYRAZIN 3 YL) 1 METHYLCYCLOBUTANOL; 3-(8-AMINO-1-(2-PHENYLQUINOLIN-7-YL)IMIDAZO(1,5-A)PYRAZIN-3-YL)-1-METHYLCYCLOBUT ANOL; DIAGNOSTIC AGENT; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; DRUG ANTAGONISM; DRUG SCREENING; LUNG TUMOR; METHODOLOGY; NUDE MOUSE; PROGNOSIS; SCINTISCANNING; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZINES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955991871     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2274     Document Type: Article

References (28)

1. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007;6:2158-67. (Pubitemid 47294744)
2. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6. (Pubitemid 28067285)
3. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6. (Pubitemid 28209997)
4. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5. (Pubitemid 29194048)
5. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-6. (Pubitemid 29042692)
6. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37. (Pubitemid 36588961)
7. Parker AS, Cheville JC, Janney CA, Cerhan JR. High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum Pathol 2002;33:801-5. (Pubitemid 34983100)
8. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873-7. (Pubitemid 37429826)
9. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer 2006;13 Suppl 1:S33-43.
10. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623.
11. Buck E, Gokhale P, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation upon inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for co-targeting IGF-1R and IR in cancer. Mol Cancer Ther 2010;9:2652-64.
12. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009;1:1153-71.
13. Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, Shah C, et al. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 2008;14:7413-22.
14. Ayers GD, McKinley ET, Zhao P, Fritz JM, Metry RE, Deal BC, et al. Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements. J Ultrasound Med ;29:891-901.
15. Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 2009;15:4712-21.
16. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 2006;47:999-1006. (Pubitemid 46939953)
17. Dandekar M, Tseng JR, Gambhir SS. Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 2007;48:602-7. (Pubitemid 47571417)
18. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24:3282-92. (Pubitemid 46622068)
19. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004;64:3892-9. (Pubitemid 38697301)
20. Clemmons DR. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 2006;6:620-5. (Pubitemid 44752640)
21. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolismand tumor cell growth. Curr Opin Genet Dev 2008;18:54-61. (Pubitemid 351694453)
22. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
23. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
24. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-82. (Pubitemid 351766797)
25. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6.
26. DeBerardinis RJ. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet Med 2008;10:767-77.
27. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-808. (Pubitemid 40525178)
28. Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, et al. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res 2007;13:3460-9. (Pubitemid 46955105)